RNXT (RenovoRx) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


RNXT RenovoRx Inc RNXT
31 GF Score
Price $0.95
! 2 Warning Signs
View Full Analysis

What is RenovoRx Tariff Resilience Score?

RenovoRx RNXT +1.47% 31 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates RNXT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,376 Biotechnology companies, RenovoRx ranks better than 90.41% on this metric.

RenovoRx has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

RenovoRx has RenovoRx Inc has limited exposure to tariffs due to its focus on the domestic healthcare market. Its supply chain is less globalized, and it has minimal import/export activities. The company can leverage pricing power in niche markets, reducing tariff impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes RenovoRx might have Highly Resilient.

RenovoRx  (NAS:RNXT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

RenovoRx Tariff Resilience Score Related Terms

RNXT vs NNVC, KALA, PSTV: Tariff Resilience Score Comparison

For the Biotechnology subindustry, RenovoRx's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RenovoRx Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where RenovoRx's Tariff Resilience Score falls into.


RNXT
31GF Score
RenovoRx Inc RNXT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
RenovoRx (RNXT) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, RenovoRx ranks #132 out of 1376 companies in the Biotechnology industry, placing it in the top 9.6%.
Is RenovoRx's Tariff Resilience Score too high?
RenovoRx's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. RenovoRx's value of 7 is 75% above this industry median. Based on the distribution chart, RenovoRx ranks #132 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RenovoRx has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does RenovoRx's Tariff Resilience Score compare to NNVC and KALA?
According to the Biotechnology industry distribution chart, RenovoRx ranks #132 out of 1376 companies for Tariff Resilience Score. This places RenovoRx in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. RenovoRx's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RenovoRx's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RenovoRx's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovoRx stock overvalued right now?
RenovoRx (RNXT) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. RenovoRx's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For RenovoRx (RNXT), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RenovoRx Business Description

Address 2570 West El Camino Real, Suite 320, Mountain View, CA, USA, 94040
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
31GF Score

Get the complete analysis for RNXT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.95
Price